The Effects of a Novel Sodium Bicarbonate Ingestion System on Repeated 4 km Cycling Time Trial Performance in Well-Trained Male Cyclists.

Abstract

A novel sodium bicarbonate (SB) product has come to market named the "Bicarb System" (M-SB; Maurten AB, Gothenburg, Sweden). It claims to minimise gastrointestinal (GI) discomfort whilst still improving exercise performance. To investigate the effects of M-SB ingestion on repeated 4 km cycling time trials (TT1 and TT2) in well-trained male cyclists. The study recruited ten well-trained cyclists (maximal oxygen uptake ( <math xmlns="http://www.w3.org/1998/Math/MathML"> <mrow><mover><mi>V</mi> <mo>˙</mo></mover> <msub><mtext>O</mtext> <mrow><mn>2</mn> <mo>max</mo></mrow> </msub> </mrow> </math> ): 67 ± 4 ml kg^-1 min^-1 BM; peak power output (PPO) at <math xmlns="http://www.w3.org/1998/Math/MathML"> <mrow><mover><mi>V</mi> <mo>˙</mo></mover> <msub><mtext>O</mtext> <mrow><mn>2</mn> <mo>max</mo></mrow> </msub> </mrow> </math> : 423 ± 21 W) to take part in this randomised, crossover and double-blinded study. Following one visit to determine <math xmlns="http://www.w3.org/1998/Math/MathML"> <mrow><mover><mi>V</mi> <mo>˙</mo></mover> <msub><mtext>O</mtext> <mrow><mn>2</mn> <mo>max</mo></mrow> </msub> </mrow> </math> , participants completed a second visit to identify individual time to peak blood bicarbonate (HCO₃^-) (ITTP) in a rested state. Visit three was a familiarisation trial mimicking the experimental procedures. Visits four to seven consisted of completing 2 × 4 km cycling TTs separated by 45 min passive recovery, following one of either: 0.3 g kg^-1 BM M-SB, 0.21 g kg^-1 BM sodium chloride (placebo; PLA) in vegetarian capsules (size 00), or a control trial (CON). Supplements (M-SB or placebo) were ingested pre-exercise at their respective ITTP. Performance in TT1 was faster in the M-SB condition compared with TT1 in CON (- 5.1 s; p = 0.004) and PLA (- 3.5 s; p < 0.001). In TT2, performance was also significantly faster in the M-SB condition compared with CON (- 4.4 s; p = 0.018) or PLA (- 4.1 s; p = 0.002). Total aggregated GI symptoms were generally low and not significantly different between PLA and the M-SB conditions for a range of symptoms. The ingestion of M-SB improves repeated 4 km cycling TT performance and the recovery of acid-base balance between bouts, whilst causing minimal GI discomfort.